Current candidate AD drugs include those that target either Aβ, APP, or tau metabolism by preventing oligomer efflux, modulating enzyme secretases, prevent aggregation, facilitate clearance and vaccination induced immunological clearance (Kumar et al., 2015). The gene discussed is APP; the disease is Alzheimer disease.